Pharmaceutical

Merck to invest €300m in South Korean bioprocessing centre

Merck KGaA has announced an investment of over €300m ($326.1m) to establish a new bioprocessing production centre in Daejeon, South Korea.

Mar 22, 2024 - 00:00
Merck to invest €300m in South Korean bioprocessing centre
Merck KGaA has announced an investment of over €300m ($326.1m) to establish a new bioprocessing production centre in Daejeon, South Korea.
Read the original article

Tags:

Previous Article

Delivery tech remains challenging with gene therapies for brain disorders

Next Article

Donanemab: FDA AdCom will put spotlight on tau enrolment and ARIA concerns

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Atypical Teratoid Rhabdoid Tumor drugs in development, ...

Aug 31, 2024

STAT+: Democrats blast Biden administration over Alzheimer’s drug plans

STAT+: Democrats blast Biden administration over Alzhei...

Jun 8, 2023

Resilience secures funds to enhance production of essential medicine components

Resilience secures funds to enhance production of essen...

Oct 6, 2024